was 59.4% in the most adherent, 36.1% in the middle group and 38.1% in the least adherent group (P ¼ 0.006). Excluding nonmelanocytic skin cancers, cancer incidence remained significantly higher in the highest adherence group (P ¼ 0.002). Conclusions. These data provide additional support for the need to individualize immunosuppression to minimize both rejection and immunosuppressive drug-related complications including cancer.
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I N T R O D U C T I O N
New drug development proceeds through three stages while determining safety and efficacy. In the later stages of drug development (Phase 2 and 3 trials), an optimal dose schedule for efficacy is determined. One weakness of these trials, however, is that it is often unknown what percentage of the subjects actually take the new drug as prescribed, and thus the final recommended dosing schedule is based on the combined outcomes of both adherent and variably nonadherent patients [1] .
Clinically there are wide variations in adherence to immunosuppressive medications. Measured or self-reported posttransplant medication nonadherence is associated with increased rates of rejection and graft loss [2] [3] [4] [5] . We previously reported that even early and more modest medication nonadherence, only detectable by electronic monitoring using medication event monitoring system (MEMS) caps, is associated with increased rates of acute rejection and late graft loss [3] . Importantly, we also demonstrated that these early medication adherence patterns appear to become habitual and remain significantly preserved over long intervals with minimal changes up to >4 years posttransplant [5] . Remarkably, electronically monitored medication adherence studies in several different clinical settings have identified similar 'early' predictive patterns. Specifically, in patients with seizures [6] , suboptimal medication adherence (<96% adherent) during the first 6 months of therapy significantly (P ¼ 0.02) predicted poorer seizure control 4 years later. Similarly, a multicenter study of chemoprophylaxis (6-mercaptopurine) for acute leukemia patients in remission demonstrated that poor (<95%) 6-month adherence during their first year in remission significantly (P ¼ 0.001) predicted leukemic relapse out to at least 6 years [7] .
It has been shown that cancer after transplantation is associated with cumulative immunosuppression exposure [8] [9] [10] [11] [12] . Thus we questioned whether those patients with the best adherence, documented by electronic monitoring, might experience an increased cancer risk.
M A T E R I A L S A N D M E T H O D S
Between August 1998 and August 2006, 1802 patients received kidney or kidney-pancreas transplants at the University of Minnesota Medical Center. Of these, 868 (48.2%) were eligible and were contacted and invited to participate in this drugmonitoring study. The criteria for eligibility were (i) ability to understand the English language (ii) using pills for immunosuppression and not suspensions, (iii) not in a nursing home care setting and (iv) patients who could be invited to participate before their index discharge after transplant. A total of 452 patients (52.1%) consented to participate. Of these, 195 patients (43%) provided data for all or part of the first study year. For these 195 patients, immunosuppressive medication adherence patterns were prospectively documented using electronic medication event monitors (MEMS-6 TrackCaps, Aardex, Sion, Switzerland) [3] . All patients received initial induction therapy with an antilymphocyte antibody. Maintenance immunosuppression consisted of a calcineurin inhibitor and an antimetabolite, with or without prednisone [13] .
Donor and recipient clinical information was collected and stored in an IRB-approved secure database. For recipients, we collected pretransplant characteristics and comorbidities, perioperative information including human leukocyte antigen matching and complications. The database also compiles longterm outcomes specifically rejection, infections and the development of comorbidities, including cancer. All recipients were followed through July 2016 for the diagnosis of cancer, rejection and infection episodes, as well as for patient and graft survival. Graft failure was defined as death, receipt of a new renal transplant or return to chronic dialysis.
Details of the medication monitoring protocol have been previously published [2, 5] . Briefly, medication monitoring using MEMS caps began at the initial hospital discharge. The monitored medication was the prescribed antimetabolite:mycophenolate mofetil (n ¼ 150), sirolimus (n ¼ 28) or azathioprine (n ¼ 17). Each time the MEMS cap was removed from the medication vial, the date and time of that event were recorded in cap memory and presumed to represent a medication dose taken. To minimize confusion about daily dose times, each patient's medication record began at 3:00 a.m. and ended the next day at 2:59 a.m.
Continuous medication dosing histories were compiled for each patient and analyzed. All study patients initiated the monitored drug therapy and no subject unilaterally discontinued their drug. The patient's chart was reviewed and all hospitalizations or dosing schedule changes were noted. When a provider temporarily discontinued a medication, the absence of a cap opening on that day was considered 'adherent'. If a patient was hospitalized, those hospital days were excluded from the calculations of average daily adherence (since the patient was not independently responsible for taking medication that day). Daily adherence implementation was quantified as the percentage of prescribed doses taken each day. The average daily adherence percent over the first 6 months posttransplant was used to classify patient adherence levels.
Statistical methods
The 195 recipients were divided into tertiles of adherence based on their calculated average 6-month adherence to the monitored immunosuppressive drug:highest adherence tertile (adherence 97.9%), middle adherence (91.0-97.8%) and lowest adherence (<91%). The highest adherence group contained 64 patients, the middle group had 66 patients and the lowest adherence group had 65 patients.
Increased risk of cancer in kidney transplant recipients Continuous clinical and demographic characteristics of the recipients were summarized as median (25th-75th percentile) and categorical characteristics were summarized as frequency (%) by tertile of 6-month adherence. Kruskal-Wallis tests (continuous covariates) and Pearson's chi-squared tests (categorical covariates) were used to test univariate differences among the tertiles.
The cancer rate per 100 patient-years at risk was calculated for each of the adherence tertiles separately for early (0-5 years), middle (5-10 years) and late (>10 years) posttransplant followup. The cumulative incidence of first posttransplant cancer over time was estimated for each tertile using product limit estimators treating death as a competing risk. Patients were censored at last-known date of graft function since follow-up ends at graft loss. We estimated the cumulative incidence separately for (i) all cancers, (ii) nonmelanocytic skin cancers and (iii) all cancers excluding nonmelanocytic skin cancers. Differences in the cumulative incidence of cancers among tertiles of adherence were compared using Gray's test.
To adjust for imbalances in clinical characteristics among the tertiles of adherence, we fit a competing risk proportional hazards model (Fine-Gray regression) with adherence tertiles, recipient age, recipient gender and prior (pretransplant) incidence of cancer as predictors of posttransplant cancer incidence. These covariates were selected due to their imbalances among the adherence groups and their association with cancer incidence.
Because patients receive additional immunosuppression to treat acute rejection, we performed sensitivity analyses in which patients were censored from follow-up at the first acute rejection episode (Supplementary data).
All analyses were performed using R version 3.3.1 (R Foundation for Statistical Computing, Vienna, Austria). All statistical analyses used two-sided tests with P < 0.05 indicating statistical significance.
R E S U L T S

Cohort description
The recipient and donor characteristics for the entire group and by adherence tertile are summarized in Table 1 . The median recipient age was 48.2 years (25th-75th percentile: 37.4-56.5 years), 43% were females, 44% had a deceased donor transplant, 36% had a living-related donor and 20% had a living-unrelated donor. Of the total, 83% of patients received a first transplant, 82% of the transplants were kidney alone and 18% had a simultaneous kidney-pancreas transplant or kidney after pancreas transplant. By study design, prospective medication adherence monitoring was planned to extend to at least 1 year. All subjects initiated their monitored immunosuppressive drug at the time of hospital discharge and no subject voluntarily discontinued the monitored drug early. Electronic monitoring for the cohort continued an average of 15.8 months. The median follow-up (time between transplant and date of last known graft function) was 10.1 years, and did not differ significantly among the adherence tertiles (P ¼ 0.96).
There was suboptimal implementation of the dosing regimen. That was quantified and expressed as the daily adherence percent averaged over the first 6 months posttransplant. When compared with the two other tertiles, the tertile with the highest adherence was more likely to be older (P ¼ 0.005) and white non-Hispanic (P ¼ 0.001) and was slightly less likely to be male (Table 1 ). There were no other significant demographic differences among the tertiles.
Cancer incidence
The incidence rates of first posttransplant cancer, by cancer type, are shown in Table 2 . The cancer rates (per 100 personyears at risk) were higher between 5 and 10 years posttransplant compared with either 1-5 years or 10-15 years posttransplant. But due to the skewed follow-up time, <35% of the patients in each tertile were available beyond 10 years. The types and sites of nonskin cancers are listed in Table 3 .
The unadjusted cumulative incidence of all cancers, treating death as a competing risk, is shown, by cancer type, in Figure 1A -C. There was a significant difference among the adherence tertiles in the cumulative incidence of all cancers (P ¼ 0.006), all cancers except nonmelanocytic skin cancers (P ¼ 0.002) and nonmelanocytic skin cancers (P ¼ 0.047). For each of these cancer types, the highest cancer incidence was observed in the most adherent group, with lower and similar incidence in the middle and lowest adherence groups. Specifically, the estimated 10-year cumulative incidence of all cancer types was 59.4% for the highest tertile, 36.1% for the middle and 38.1% for the lowest tertile. For all cancers excluding nonmelanocytic skin cancers, the 10-year incidence for the highest tertile was 27.9%, for the middle it was 12.7% and for the lowest it was 9.9%. For nonmelanocytic skin cancers, the 10-year incidence for the highest tertile was 49.2%, for the middle it was 29.2% and for the lowest it was 33.8%.
The estimated association between adherence group and the cancer subdistribution hazard after adjusting for recipient age, gender and prior (pretransplant) cancer is shown in Table 4 . Adherence group remained a significant factor in the cumulative incidence of cancer across all cancer types (P overall ¼ 0.015 for all cancers, P overall ¼ 0.014 for all cancers except nonmelanocytic skin cancers and P overall ¼ 0.038 for nonmelanocytic skin cancers). Specifically, the subdistribution hazard for all cancers excluding nonmelanocytic skin cancers were 71% [95% confidence interval (CI) 18-90)] and 60% (8-82) lower for the Increased risk of cancer in kidney transplant recipients lowest and middle adherence tertiles, respectively, as compared with the most adherent group. Similar results were obtained when the follow-up was censored at the first acute rejection episode (see Supplementary data).
D I S C U S S I O N
Since the beginning of clinical transplantation, immunosuppressive protocols have been developed by attempting to balance the risks of underimmunosuppression (e.g. increased rates of acute rejection, graft loss) with the risks of overimmunosuppression (increased rates of side effects, including cancer and infection). However, in general, immunosuppression protocols have evolved without any discrete data regarding patient medication adherence or compiled dosing histories.
We and other groups have shown that underimmunosuppression secondary to nonadherence is a major risk factor (perhaps the major risk factor) for late posttransplant development of de novo donor-specific antibody, acute rejection and graft loss [2] [3] [4] [5] [14] [15] [16] [17] . In addition, we have shown that even subclinical (i.e. only detected by electronic monitoring) medication nonadherence is associated with increased rates of acute rejection and graft loss. The present analysis demonstrates that ideal adherence (>97.9% of doses taken) is associated with an increased cancer risk, including both a higher rate and earlier appearance of malignancies.
It is known that the risk of cancer is significantly increased after solid organ transplantation. For example, depending on geography (and associated sun exposure), skin cancers have been reported to occur in 50-80% of kidney transplant recipients after 20 years of immunosuppression [8, 12, [18] [19] [20] . Importantly, cancer risk has also been correlated with cumulative exposure to immunosuppression [7-11, 18, 21, 22] . Buell et al. [8, 23] estimated that after 10 years of chronic immunosuppression, the incidence of cancer is 20%. Vajdic et al. [24] , analyzing the Australia and New Zealand Dialysis and Transplant Registry, reported that transplant recipients have a >3-fold increased risk of nonskin cancers, especially genitourinary tract cancers, melanomas, connective tissue cancers, thyroid and other endocrine cancers. The risk of developing some cancers, especially those associated with a viral pathogenesis (e.g. lymphoma, skin cancer and cancer of the cervix), is even higher [8, [18] [19] [20] [21] 24] . Notably, although lymphoma is relatively rare in the general population, 'posttransplant lymphoproliferative disease', has been reported in up to 11% of kidney transplant patients [8, 25, 26] .
In this current study we found that the transplant patients who were most adherent with their immunosuppression experienced the highest cancer rates (Table 2 ) and, additionally, those cancers appeared significantly earlier ( Figure 1A-C) . This was true when we studied all cancers combined, or more critically, in all cancers other than nonmelanocytic skin cancers (Table 2) . Interestingly, compared with the other adherence tertiles, only the patients in the tertile with almost perfect adherence (>97.9% adherence) consistently experience the highest cancer risks. The patients in the middle and lowest tertiles had similarly elevated, but lower overall rates of cancer.
Recognizing these elevated posttransplant cancer risks highlights the need to consistently follow the recommended cancer surveillance protocols, collegially involving the patient's primary care physician as well as local dermatologists [27] . It should also stimulate the search for proactive strategies to reduce cancer risks, including vaccines (human papilloma virus, Epstein-Barr virus), antiviral therapies [21] , supplements (nicotinamide) [28] and promotion of healthier lifestyles (diet, smoking cessation, etc.).
Prospective surveillance of medication adherence, including serial drug levels, prescription refill histories, patient questionnaires and perhaps electronic medication monitoring, should become routine. Indeed, Neuberger et al. [29] have recommended including monitoring of adherence posttransplant as the 'fifth vital sign'. Ultimately such information may support opportunities to individually tailor immunosuppressive drug treatment in suitable patients while preserving graft function and survival, as well as minimizing cancer risks. Ideally in the future, protocols and immune monitoring assays will be developed that facilitate better individualized immunosuppression.
Our study is strengthened by the consistency and length of follow-up for the entire cohort, as well as by the ability to prospectively quantitate daily medication adherence by MEMS. Most of these study patients were very adherent, and prospectively the differences between the best tertile (>98%) and the lowest adherence tertile (<91%) are likely only discernable by electronic monitors. Our earlier studies consistently demonstrated that lower medication adherence predicted adverse outcomes for renal transplant patients [2, 3, 5] . When followed by MEMS, we demonstrated that the adherence tertiles remain fairly consistent out to 4 years posttransplant [5] . Our observations are further supported by other studies that measured early medication adherence for 6 months, by MEMS, and found those results similarly predicted clinical events 4-6 years later [6, 7] . In each of these studies the 'best' adhering patients also demonstrated adherence percentages >95%.
However, this study does have several limitations. It is a single-center study and thus is limited by center-specific populations and treatment practices. Our sample size of 195 patients is relatively small; however, even with this smaller sample we found significantly increased early cancer incidence and rates in the most adherent recipients. Clearly these observations need to be replicated in a larger group of patients followed for a longer time. Also, as with all studies based on electronic monitoring, cap removal does not guarantee medication ingestion. However, it is unlikely that a patient would remember to open the cap once or twice a day and then choose not to take the medication at that time. Patients were only monitored for adherence in the early posttransplant period (mean 15.8 months), yet the increased cancer rates appeared later. It may be that adherence patterns had changed over time, but we have previously demonstrated, in two separate cohorts of renal transplant recipients [3, 5] , that early immunosuppressive adherence patterns are highly predictive of long-term adherence. Finally, we could not control for behavioral and other risk factors (such as smoking), which could contribute to an increased cancer risk.
In conclusion, excellent medication adherence to posttransplant immunosuppression, while lowering acute rejection rates and increasing long-term graft survival, is associated with a significantly increased cancer risk. Despite this, from a patient's perspective, the overall risks to life and health are still much lower with a functioning renal transplant. Providers need to carefully explain these relative risks to patients to avoid any patient unilaterally adjusting their immunosuppression. At the same time, patients need to be actively engaged in both preventive strategies and proactive cancer surveillance protocols. Immune monitoring to better calibrate immunosuppression and the overall immune status in a transplant patient remains a future goal. Currently, personalized immunosuppression based on individual immunologic risk assessment, therapeutic drug An 'overall' or 'composite' test for adherence group after adjusting for recipient age, race/ethnicity, gender and prior cancer was significant for all cancer types (P overall ¼ 0.015 for all cancers, P overall ¼ 0.014 for all cancers except nonmelanocytic skin cancers and P overall ¼ 0.038 for nonmelanocytic skin cancers). HR, subdistribution hazard ratio; 95% CI LB, lower bound of 95% confidence interval for the hazard ratio; 95% CI UB, upper bound of 95% confidence interval for the hazard ratio; Tx, transplant.
monitoring and attention to medication adherence has the potential to decrease rejection, and graft loss, while also reducing other adverse outcomes, including cancer. Adequately powered prospective clinical trials will be needed to identify suitable patients and then determine how to best achieve this balance.
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